BoradMJLoRussoPM.Twenty-First century precision medicine in oncology: genomic profiling in patients with cancer. Mayo Clin Proc2017;
92: 1583–1591.
3.
DavisAAMcKeeAEKibbeWA, et al.
Complexity of delivering precision medicine: opportunities and challenges. Am Soc Clin Oncol Educ Book2018;
38: 998–1007.
4.
LeDTUramJNWangH, et al.
PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med2015;
372: 2509–2520.
5.
AmatuASartore-BianchiASienaS.NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open2016;
1: e000023.
6.
VaishnaviALeATDoebeleRC.TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov2015;
5: 25–34.
ChenYChiP.Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers. J Hematol Oncol2018;
11: 78–06.
9.
Meric-BernstamFJohnsonAHollaV, et al.
A decision support framework for genomically informed investigational cancer therapy. J Natl Cancer Inst2015;
107: 04–12.
10.
OffinMLiuDDrilonA.Tumor-agnostic drug development. Am Soc Clin Oncol Educ Book2018;
38: 184–187.
11.
LuohSWFlahertyKT.When tissue is no longer the issue: tissue-agnostic cancer therapy comes of age. Ann Intern Med2018;
169: 233–239.
12.
MateoJChakravartyDDienstmannR, et al.
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO scale for clinical actionability of molecular targets (ESCAT). Ann Oncol2018;
29: 1895–1902.
13.
DrilonALaetschTWKummarS, et al.
Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med2018;
378: 731–739.
14.
ManoH.ALKoma: a cancer subtype with a shared target. Cancer Discov2012;
2: 495–502.
15.
ZitoMFPagliucaFRonchiA, et al.
NTRK fusions, from the diagnostic algorithm to innovative treatment in the era of precision medicine. Int J Mol Sci2020;
21: 05–30.
16.
WalkerA.Neurotrophic tyrosine kinase inhibitors: a review of implications for patients, clinicians and healthcare services. J Oncol Pharm Pract2020;
26: 2015–2019.
